# Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

Study · id `cardio:ct-nct01687491` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01687491](<https://clinicaltrials.gov/study/NCT01687491>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01687491

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

## Technical summary

Registry record NCT01687491. Randomized; single masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 179 participants (enrolled count; ClinicalTrials.gov record NCT01687491, source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01687491, source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01687491, source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01687491, source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)
- Countries: Tunisia (ClinicalTrials.gov record NCT01687491, source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01687491-2015-11-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
- Acronym: AXA
- Condition: Acute Coronary Syndrome
- Condition: Factor X
- Intervention (Drug): ENOXA®
- Intervention (Drug): LOVENOX®
- Lead sponsor: Les Laboratoires des Médicaments Stériles
- Lead sponsor class: INDUSTRY
- Collaborator: University Hospital Fattouma Bourguiba
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

## Provenance

Content hash: 954e2fb97d21acc44bd869629056bdef8ca13aefa01214e2c81a6c11ef38a090
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
